

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for April 2025

Complete Streamlined Multiple-Source Submissions for Future Formulary Listing

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for listing on the Ontario Drug Benefit Formulary. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be listed as benefits in a future Formulary update. Final listing status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Jamp Pharma Corporation	Jamp Dutasteride	Avodart	DUTASTERIDE	0.5 mg	capsule	02546167
Apotex Inc.	Apo-Eslicarbazepine	Aptiom	ESLICARBAZEPINE ACETATE	200 mg	tablet	02537931
Apotex Inc.	Apo-Eslicarbazepine	Aptiom	ESLICARBAZEPINE ACETATE	400 mg	tablet	02537958

Apotex Inc.	Apo-Eslicarbazepine	Aptiom	ESLICARBAZEPINE ACETATE	600 mg	tablet	02537966
Apotex Inc.	Apo-Eslicarbazepine	Aptiom	ESLICARBAZEPINE ACETATE	800 mg	tablet	02537974
Jamp Pharma Corporation	Jamp Nitrofurantoin	Macrochantin	NITROFURANTOIN	50 mg	capsule	02495503
Jamp Pharma Corporation	Jamp Nitrofurantoin	Macrochantin	NITROFURANTOIN	100 mg	capsule	02495511
Mantra Pharma Inc.	M-Tranylcypromine	Parnate	TRANLYCYPROMINE SULFATE	10 mg	tablet	02542188
Apotex Inc.	Apo-Vortioxetine	Trintellix	VORTIOXETINE HYDROBROMIDE	5 mg	tablet	02552744
Apotex Inc.	Apo-Vortioxetine	Trintellix	VORTIOXETINE HYDROBROMIDE	10 mg	tablet	02552752
Apotex Inc.	Apo-Vortioxetine	Trintellix	VORTIOXETINE HYDROBROMIDE	20 mg	tablet	02552779
Sandoz Canada Inc.	Sandoz Oseltamivir	Tamiflu	OSELTAMIVIR PHOSPHATE	30 mg	capsule	02504006
Sandoz Canada Inc.	Sandoz Oseltamivir	Tamiflu	OSELTAMIVIR PHOSPHATE	45 mg	capsule	02504014
Sandoz Canada Inc.	Sandoz Oseltamivir	Tamiflu	OSELTAMIVIR PHOSPHATE	75 mg	capsule	02504022